Short Interest in Immix Biopharma, Inc. (NASDAQ:IMMX) Rises By 17.5%

Immix Biopharma, Inc. (NASDAQ:IMMX) saw a large growth in short interest in November. As of November 30th, there was short interest totalling 470,700 shares, a growth of 17.5% from the November 15th total of 400,700 shares. Currently, 2.9% of the shares of the company are short sold. Based on an average trading volume of 159,400 shares, the days-to-cover ratio is presently 3.0 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and issued a $7.00 price target on shares of Immix Biopharma in a research report on Thursday, October 3rd.

Hedge Funds Weigh In On Immix Biopharma

An institutional investor recently bought a new position in Immix Biopharma stock. Invst LLC acquired a new stake in shares of Immix Biopharma, Inc. (NASDAQ:IMMX) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 27,000 shares of the company’s stock, valued at approximately $57,000. Invst LLC owned about 0.10% of Immix Biopharma as of its most recent SEC filing. Institutional investors own 11.26% of the company’s stock.

Immix Biopharma Stock Performance

Shares of Immix Biopharma stock traded up $0.07 during trading hours on Monday, hitting $2.11. The company’s stock had a trading volume of 80,958 shares, compared to its average volume of 184,224. The company has a market cap of $58.04 million, a PE ratio of -2.47 and a beta of 0.28. The business has a 50 day moving average price of $1.78 and a two-hundred day moving average price of $1.93. Immix Biopharma has a 12-month low of $1.26 and a 12-month high of $7.75.

Immix Biopharma (NASDAQ:IMMX) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.08). As a group, research analysts anticipate that Immix Biopharma will post -0.64 earnings per share for the current year.

About Immix Biopharma

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.